Information for the public
Nemolizumab (Nemluvio) is available on the NHS. It is a possible treatment alongside topical corticosteroids or calcineurin inhibitors, or both, for moderate to severe atopic dermatitis (eczema) in people 12 years and over when:
- their body weight is 30 kg or more
- systemic treatment is suitable
- the atopic dermatitis has not responded to at least 1 systemic immunosuppressant, or these treatments are not suitable
- a biological medicine would otherwise be offered.
Systemic treatments work throughout the whole body. They can include injections, infusions or medicines taken by mouth. Nemolizumab is given by injection.
If your atopic dermatitis does not improve enough, nemolizumab will be stopped after 16 weeks. When assessing how much it has improved, healthcare professionals should take into account how the atopic dermatitis may look on your skin colour.
When assessing how atopic dermatitis affects your quality of life, healthcare professionals should take into account any disabilities or difficulties in communicating you might have.
If you are not eligible for nemolizumab but are already having it, you should be able to continue until you and your doctor decide when best to stop.
Is this treatment right for me or my child?
Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See our webpage on making decisions about your care.
Questions to think about
- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?
Information and support
The NHS webpage on atopic eczema may be a good place to find out more.
Eczema Outreach Support (01506 840395) can give you advice and support.
You can also get support from your local Healthwatch.
NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.
ISBN: 978-1-4731-7083-4
This page was last updated: